Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast Ultrasound Response in PsA
NCT03191539Phase 3Unknown
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Nov 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of apremilast in psoriatic arthritis (PsA), sponsored by Vall d'Hebron Research Institute. Primary endpoint: Reduction in the ultrasound index at 12 months. Status: unknown.
02
Drugs
apremilast
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT03191539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03191539.